REPCF (0913693 BC) Shiller PE Ratio: (As of Aug. 25, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is 0913693 BC Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


0913693 BC  (OTCPK:REPCF) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


0913693 BC Shiller PE Ratio Related Terms


0913693 BC Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for 0913693 BC's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

0913693 BC Shiller PE Ratio Chart

0913693 BC Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

0913693 BC Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

REPCF vs VRTX, REGN, SGEN: Shiller PE Ratio Comparison

For the Biotechnology subindustry, 0913693 BC's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


0913693 BC Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 0913693 BC's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where 0913693 BC's Shiller PE Ratio falls into.



0913693 BC Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

0913693 BC's E10 for the quarter that ended in Sep. 2023 is calculated as:

For example, 0913693 BC's adjusted earnings per share data for the three months ended in Sep. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=-0.007/125.2304*125.2304
=-0.007

Current CPI (Sep. 2023) = 125.2304.

0913693 BC Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201312 -0.203 96.945 -0.262
201403 -0.270 98.604 -0.343
201406 -0.277 99.473 -0.349
201409 -0.182 99.394 -0.229
201412 -0.191 98.367 -0.243
201503 -0.159 99.789 -0.200
201506 -0.202 100.500 -0.252
201509 -0.143 100.421 -0.178
201512 -0.160 99.947 -0.200
201603 -0.129 101.054 -0.160
201606 -0.093 102.002 -0.114
201609 -0.076 101.765 -0.094
201612 -0.085 101.449 -0.105
201703 -0.075 102.634 -0.092
201706 -0.105 103.029 -0.128
201709 -0.049 103.345 -0.059
201712 -0.016 103.345 -0.019
201803 -0.023 105.004 -0.027
201806 -0.023 105.557 -0.027
201809 -0.031 105.636 -0.037
201812 -0.030 105.399 -0.036
201903 -0.022 106.979 -0.026
201906 -0.023 107.690 -0.027
201909 -0.015 107.611 -0.017
201912 -0.030 107.769 -0.035
202003 -0.007 107.927 -0.008
202006 -0.007 108.401 -0.008
202009 -0.015 108.164 -0.017
202012 -0.008 108.559 -0.009
202103 -0.032 110.298 -0.036
202106 -0.025 111.720 -0.028
202109 -0.024 112.905 -0.027
202112 -0.023 113.774 -0.025
202203 -0.016 117.646 -0.017
202206 -0.023 120.806 -0.024
202209 -0.022 120.648 -0.023
202212 0.022 120.964 0.023
202303 -0.007 122.702 -0.007
202306 -0.008 124.203 -0.008
202309 -0.007 125.230 -0.007

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


0913693 BC Business Description

Address 570 Granville Street, Suite 900, Vancouver, BC, CAN, V6C 3P1
0913693 BC Ltd is a regenerative medicine company focused on aesthetics and orthopedics. It is a royalty company that holds its primary royalty assets focused on autologous cell therapies that treat functional cellular deficits, including chronic tendon injuries, androgenetic alopecia, and skin aging. The Company is organized into one business unit based on its cell replication technology and has one reportable operating segment. Its product line is RCT-01 Tendon Repair, RCS-01 Skin Rejuvenation, RCH-01 Hair Growth, and DermaPrecise.